Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.

ABSTRACT:

Introduction

The negative efficacy results of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) as early treatment in the COnV-ert trial have been attributed to the use of methylene blue (MB). We characterized immune responses after MB-treated CCP infusion and the impact of MB on antibodies of the infused CCP units.

Methods

We measured antibody isotypes (IgG, IgM, and IgA) and IgG subclasses (IgG1, IgG2, IgG3, and IgG4) against SARS-CoV-2 nucleocapsid and spike (S) antigens, neutralizing antibody titers, and IgG avidity in 128 participants of the COnV-ert trial 7 and 60 days after infusion and in paired CCP units before and after MB treatment.

Results

Treatment with CCP significantly increased the levels of IgG and IgG1 to receptor-binding domain (RBD) and

SUBMITTER: Alemany A 

PROVIDER: S-EPMC12507808 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature